CFTR modulators increase risk of acute pancreatitis in pancreatic insufficient patients with cystic fibrosis

This publication has 7 references indexed in Scilit:

• Pancreatitis in A Patient with Cystic Fibrosis Taking Ivacaftor
  Children, 2020
• Time for a gut check: Pancreatic sufficiency resulting from CFTR modulator use
  Pediatric Pulmonology, 2019
• Safety, pharmacokinetics, and pharmacodynamics of lumacaftor and ivacaftor combination therapy in children aged 2–5 years with cystic fibrosis homozygous for F508del-CFTR: an open-label phase 3 study
  The Lancet Respiratory Medicine, 2019
• Efficacy and safety of lumacaftor and ivacaftor in patients aged 6–11 years with cystic fibrosis homozygous for F508del-CFTR : a randomised, placebo-controlled phase 3 trial
  The Lancet Respiratory Medicine, 2017
• Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2–5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study
  The Lancet Respiratory Medicine, 2016
• Definitions of Pediatric Pancreatitis and Survey of Present Clinical Practices
  Journal of Pediatric Gastroenterology and Nutrition, 2012
• Type of CFTR Mutation Determines Risk of Pancreatitis in Patients With Cystic Fibrosis
  Gastroenterology, 2011